et al . et al . et al . et al . et al .
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

US physicians’ intentions regarding impact of human papillomavirus vaccine on cervical cancer screening

Charlene Wong A C , Zahava Berkowitz A , Mona Saraiya A , Louise Wideroff B and Vicki B. Benard A
+ Author Affliations
- Author Affliations

A Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop K-55, Atlanta, GA 30341, USA.

B National Cancer Institute, 6001 Executive Blvd., Suite 5153 MSC 9589, Bethesda, MD 20892-9589, USA.

C Corresponding author. Email: hrl5@cdc.gov

Sexual Health 7(3) 338-345 https://doi.org/10.1071/SH09115
Submitted: 29 October 2009  Accepted: 28 January 2010   Published: 19 August 2010

Abstract

Background: US cervical cancer screening recommendations have not changed since the human papillomavirus (HPV) vaccine introduction in 2006, but epidemiological and cost-effectiveness studies indicate that recommendations will need to change for fully vaccinated women. We evaluated physician intentions regarding HPV vaccine’s impact on future screening. Methods: A nationally representative sample of 1212 primary care physicians was surveyed in 2006–2007 (response rate: 67.5%). Our study included 1114 physicians who provided Pap testing. Questions covered Pap test screening practices and intentions regarding HPV vaccine’s impact on screening. Distribution differences were assessed using χ2 statistics; multivariate analyses were performed. Results: Overall, 40.7% (95% confidence interval (CI): 37.6–43.8%) of physicians agreed that the HPV vaccine will affect screening initiation, and 38.2% (35.0–41.5%) agreed that vaccination will affect screening frequency. Significant differences in responses were found by specialty; internists were more likely to agree that vaccination would impact screening than other specialties. Belief in the effectiveness of new screening technologies was associated with intention to change screening initiation (odds ratio (OR) = 1.66 (1.20–2.31)) and frequency (OR = 1.99 (1.40–2.83)). Adherence to current Pap test screening interval guidelines was associated with intention to change screening frequency (OR = 1.39 (1.01–1.91)). Conclusions: Many providers anticipate adjusting screening for vaccinated women, but a significant group believes nothing will change or are unsure. The present study provides important baseline data on intentions in the period preceding widespread vaccine diffusion and may help explain current and future trends in practice patterns.

Additional keywords: Pap cytology, prevention.


Acknowledgements

Selected data were presented at the 2009 International Papillomavirus Conference. We thank Dr Carrie Klabunde of the National Cancer Institute and Dr Caroline McLeod of WESTAT (Rockville, MD, USA) for survey research work. Charlene Wong completed this project during her 1-year fellowship The CDC Experience, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.


References


[1] Markowitz LE,  Dunne EF,  Saraiya M,  Lawson HW,  Chesson H,  Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 1–24.
PubMed |

[2] Saslow D,  Castle PE,  Cox JT,  Davey DD,  Einstein MH,  Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57 7–28.
CrossRef | PubMed |

[3] Committee on Adolescent Health Care ACOG Working Group on Immunization ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol 2006; 108 699–705.
PubMed |

[4] American College of Obstetrics and Gynecology (ACOG) Practice Bulletin No 109: Cervical Cytology Screening. Obstet Gynecol 2009; 114 1409–20.
PubMed |

[5] Garnett GP,  Kim JJ,  French K,  Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24(Suppl. 3): S3/178–86.
CrossRef |

[6] Kulasingam SL,  Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290 781–9.
CrossRef | PubMed |

[7] Franco EL,  Cuzick J,  Hildesheim A,  de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24(Suppl. 3): S3/171–7.
CrossRef |

[8] Myers E,  Huh WK,  Wright JD,  Smith JS. The current and future role of screening in the era of HPV vaccination. Gynecol Oncol 2008; 109 S31–9.
CrossRef | PubMed |

[9] Castle PE,  Solomon D,  Saslow D,  Schiffman M. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer 2008; 113 3031–5.
CrossRef | PubMed |

[10] Adams M,  Jasani B,  Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007; 25 3007–13.
CrossRef | PubMed |

[11] Massad LS,  Einstein M,  Myers E,  Wheeler CM,  Wentzensen N,  Solomon D. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 2009; 114 360–4.
CrossRef | PubMed |

[12] Centers for Disease Control and Prevention National, state and local area vaccination coverage among adolescents aged 13–17 years – United States, 2008. MMWR Recomm Rep 2009; 58 997–1001.


[13] Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111 145–53.
CrossRef | PubMed |

[14] The FUTURE II Study Group Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369 1861–8.
CrossRef | PubMed |

[15] Saslow D,  Runowicz CD,  Solomon D,  Moscicki AB,  Smith RA,  Eyre HJ, et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. J Low Genit Tract Dis 2003; 7 67–86.
CrossRef | PubMed |

[16] American College of Obstetrics and Gynecology Cervical Cytology Screening. ACOG Practice Bulletin 2003; 102 417–27.
PubMed |

[17] U.S. Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Available at: http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm [verified November 2008].

[18] Yabroff KR,  Saraiya M,  Meissner HI,  Haggstrom DA,  Wideroff L,  Yuan G, et al. Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med 2009; 151 602–11.
PubMed |

[19] Lomas J,  Enkin M,  Anderson GM,  Hannah WJ,  Vayda E,  Singer J. Opinion leaders vs audit and feedback to implement practice guidelines. Delivery after previous caesarean section. JAMA 1991; 265 2202–7.
CrossRef | PubMed |

[20] Greco PJ,  Eisenberg JM. Changing physicians’ practices. N Engl J Med 1993; 329 1271–4.
CrossRef | PubMed |

[21] Meissner HTJ,  Yabroff R,  Haggstrom D,  Coughlin S. Too much of a good thing? Physician practices and patient willingness for less frequent Pap test screening intervals. Med Care 2010; 48 256–66.
CrossRef |

[22] Cooper CP,  Saraiya M,  McLean TA,  Hannan J,  Liesmann JM,  Rose SW, et al. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. J Women’s Health 2005; 14 670–8.
CrossRef |

[23] Saint M,  Gildengorin G,  Sawaya GF. Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. Am J Obstet Gynecol 2005; 192 414–21.
CrossRef | PubMed |

[24] Murphy PA,  Schwarz EB,  Dyer JM. Cervical cancer screening practices of certified nurse-midwives in the United States. J Midwifery Womens Health 2008; 53 11–18.
CrossRef | PubMed |

[25] Holland-Barkis P,  Forjuoh SN,  Couchman GR,  Capen C,  Rascoe TG,  Reis MD. Primary care physicians’ awareness and adherence to cervical cancer screening guidelines in Texas. Prev Med 2006; 42 140–5.
CrossRef | PubMed |

[26] Schwartz LM,  Woloshin S,  Fowler FJ,  Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004; 291 71–8.
CrossRef | PubMed |

[27] Sirovich BE,  Woloshin S,  Schwartz LM. Screening for cervical cancer: will women accept less? Am J Med 2005; 118 151–8.
CrossRef | PubMed |

[28] Veloski J,  Tai S,  Evans AS,  Nash DB. Clinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual 2005; 20 151–7.
CrossRef | PubMed |

[29] Saraiya M,  Irwin KL,  Carlin L,  Chen X,  Jain N,  Benard V, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer 2007; 110 1024–32.
CrossRef | PubMed |

[30] Saraiya M,  Berkowitz Z,  Yabroff R,  Benard V,  Wideroff L,  Kobrin S. Screening with Human Papillomavirus and the Pap Test Vs. Pap Test Alone: What screening intervals are physicians recommending? Arch Intern Med ;
PubMed |

[31] Lomas J,  Anderson GM,  Domnick-Pierre K,  Vayda E,  Enkin MW,  Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989; 321 1306–11.
CrossRef | PubMed |



Rent Article (via Deepdyve) Export Citation Cited By (6)